Edwards Lifesciences Future Growth
Future criteria checks 3/6
Edwards Lifesciences se prevé un crecimiento anual de los beneficios y los ingresos de 9.5% y 8.5% respectivamente. Se prevé que el BPA sea de grow en 9.2% al año. Se prevé que la rentabilidad de los fondos propios sea de 21.4% en 3 años.
Key information
9.1%
Earnings growth rate
8.9%
EPS growth rate
Medical Equipment earnings growth | 18.2% |
Revenue growth rate | 8.5% |
Future return on equity | 22.2% |
Analyst coverage | Good |
Last updated | 08 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 7,833 | 2,003 | 1,848 | 2,130 | 20 |
12/31/2025 | 7,160 | 1,825 | 1,676 | 1,968 | 29 |
12/31/2024 | 6,520 | 1,622 | 1,361 | 1,708 | 30 |
12/31/2023 | 6,005 | 1,402 | 630 | 896 | N/A |
9/30/2023 | 5,819 | 1,431 | 788 | 1,042 | N/A |
6/30/2023 | 5,657 | 1,390 | 682 | 940 | N/A |
3/31/2023 | 5,501 | 1,489 | 985 | 1,239 | N/A |
12/31/2022 | 5,382 | 1,522 | 953 | 1,218 | N/A |
9/30/2022 | 5,364 | 1,459 | 1,040 | 1,309 | N/A |
6/30/2022 | 5,355 | 1,455 | 1,261 | 1,531 | N/A |
3/31/2022 | 5,357 | 1,539 | 1,428 | 1,725 | N/A |
12/31/2021 | 5,233 | 1,503 | 1,402 | 1,732 | N/A |
9/30/2021 | 5,095 | 1,477 | 1,409 | 1,758 | N/A |
6/30/2021 | 4,925 | 1,462 | 1,050 | 1,443 | N/A |
3/31/2021 | 4,474 | 851 | 717 | 1,148 | N/A |
12/31/2020 | 4,386 | 823 | 647 | 1,054 | N/A |
9/30/2020 | 4,369 | 794 | 692 | 1,057 | N/A |
6/30/2020 | 4,322 | 744 | 941 | 1,279 | N/A |
3/31/2020 | 4,484 | 1,108 | 1,087 | 1,389 | N/A |
12/31/2019 | 4,348 | 1,047 | 905 | 1,183 | N/A |
9/30/2019 | 4,152 | 774 | 809 | 1,073 | N/A |
6/30/2019 | 3,964 | 725 | 705 | 978 | N/A |
3/31/2019 | 3,821 | 765 | 523 | 777 | N/A |
12/31/2018 | 3,723 | 722 | 685 | 927 | N/A |
9/30/2018 | 3,634 | 712 | 754 | 998 | N/A |
6/30/2018 | 3,549 | 657 | 772 | 966 | N/A |
3/31/2018 | 3,447 | 560 | 821 | 1,024 | N/A |
12/31/2017 | 3,435 | 584 | 825 | 1,001 | N/A |
9/30/2017 | 3,315 | 745 | N/A | 838 | N/A |
6/30/2017 | 3,232 | 716 | N/A | 733 | N/A |
3/31/2017 | 3,150 | 657 | N/A | 726 | N/A |
12/31/2016 | 2,964 | 570 | N/A | 704 | N/A |
9/30/2016 | 2,867 | 552 | N/A | 607 | N/A |
6/30/2016 | 2,743 | 528 | N/A | 604 | N/A |
3/31/2016 | 2,601 | 515 | N/A | 584 | N/A |
12/31/2015 | 2,494 | 495 | N/A | 550 | N/A |
9/30/2015 | 2,441 | 463 | N/A | 539 | N/A |
6/30/2015 | 2,433 | 440 | N/A | 349 | N/A |
3/31/2015 | 2,391 | 874 | N/A | 957 | N/A |
12/31/2014 | 2,323 | 811 | N/A | 1,022 | N/A |
9/30/2014 | 2,241 | 777 | N/A | 1,040 | N/A |
6/30/2014 | 2,129 | 759 | N/A | 1,160 | N/A |
3/31/2014 | 2,071 | 306 | N/A | 511 | N/A |
12/31/2013 | 2,046 | 389 | N/A | 473 | N/A |
9/30/2013 | 2,020 | 405 | N/A | 476 | N/A |
6/30/2013 | 1,972 | 398 | N/A | 475 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: EWL(9.5% al año) es superior a la tasa de ahorro (0.6%).
Beneficios frente mercado: EWLSe prevé que los beneficios de la empresa (9.5% al año) crezcan menos que el mercado German (13% al año).
Beneficios de alto crecimiento: EWLSe prevé que los beneficios de la empresa crezcan, pero no significativamente.
Ingresos vs. Mercado: EWLSe prevé que los ingresos de la empresa (8.8% al año) crezcan más deprisa que los del mercado German (4.6% al año).
Ingresos de alto crecimiento: EWLSe prevé que los ingresos de la empresa (8.5% al año) crezcan más despacio que 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): EWLse prevé que la Rentabilidad de los fondos propios sea alta dentro de 3 años (21.4%)